FIELD: pharmacology.
SUBSTANCE: multivalent antigenic composition contains an adjuvant and two or more polypeptide, where two or more polypeptide include: I) polypeptide containing a sequence of α-lactalbumin SEQ ID NO: 1, and polypeptide containing sequence αS1-casein SEQ ID NO: 2; II) polypeptide containing a sequence of α-lactalbumin SEQ ID NO: 1, and polypeptide containing the sequence β-casein SEQ ID NO: 3; or III) polypeptide containing the sequence α-lactalbumin SEQ ID NO: 1, and polypeptide containing the sequence κ-casein SEQ ID NO: 4. The group of inventions also relates to a method of induction of an antigen-specific immune response, as well as a method of activating human T-cells in vitro. Activation of T-cells, which are CD4 + and CD8 + cells.
EFFECT: induction of inflammatory response, specific breast tissue, in a patient.
21 cl, 27 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DNA COMPOSITION FOR INDUCING IMMUNE RESPONSE ON TUMOUR-ASSOCIATED MACROPHAGUES | 2007 |
|
RU2459631C2 |
| PEPTIDE VACCINES FOR CANCER EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES | 2007 |
|
RU2469044C2 |
| HOMODIMER PROTEIN CONSTRUCTION | 2011 |
|
RU2624041C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
| VERSIONS OF IL-21 | 2006 |
|
RU2412199C2 |
| AMPLIFIER T-CELL RESPONSE TO VACCINE | 2018 |
|
RU2794196C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| IMMUNOPROPHYLACTIC CANCER VACCINE | 2004 |
|
RU2556128C2 |
| POLYPEPTIDES | 2011 |
|
RU2581800C2 |
